Connection

William Hrushesky to Antineoplastic Agents

Back to Details
This is a "connection" page, showing publications William Hrushesky has written about Antineoplastic Agents.
William Hrushesky
Connection Strength
2.201
Antineoplastic Agents
  1. Interpretation of surrogate endpoints in the era of the 21st Century Cures Act. BMJ. 2016 Dec 30; 355:i6286.
    View in: PubMed
    Score: 0.320
  2. Chronotherapy of ovarian cancer: effect on blood variables and serum cytokines. A case report. Clin Ter. 2006 Jul-Aug; 157(4):349-54.
    View in: PubMed
    Score: 0.155
  3. A recent illustration of some essentials of circadian chronotherapy study design. J Clin Oncol. 2004 Jul 15; 22(14):2971-2; author reply 2972.
    View in: PubMed
    Score: 0.135
  4. The First 2?Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions. Oncologist. 2021 08; 26(8):e1418-e1426.
    View in: PubMed
    Score: 0.107
  5. End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia. PLoS One. 2020; 15(6):e0234541.
    View in: PubMed
    Score: 0.102
  6. End of an era for erythropoiesis-stimulating agents in oncology. Int J Cancer. 2020 05 15; 146(10):2829-2835.
    View in: PubMed
    Score: 0.100
  7. Caveat Medicus: Clinician experiences in publishing reports of serious oncology-associated adverse drug reactions. PLoS One. 2019; 14(7):e0219521.
    View in: PubMed
    Score: 0.096
  8. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada. Oncologist. 2019 04; 24(4):537-548.
    View in: PubMed
    Score: 0.093
  9. Generic oncology drugs: are they all safe? Lancet Oncol. 2016 Nov; 17(11):e493-e501.
    View in: PubMed
    Score: 0.079
  10. Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia. Br J Haematol. 2018 01; 180(2):301-304.
    View in: PubMed
    Score: 0.079
  11. Larry Scheving and cancer chronotherapy. J Infus Chemother. 1995; 5(1):1-2.
    View in: PubMed
    Score: 0.070
  12. Cancer chronotherapy: is there a right time in the day to treat? J Infus Chemother. 1995; 5(1):38-43.
    View in: PubMed
    Score: 0.070
  13. Biological perspectives on circadian cancer therapy. J Infus Chemother. 1995; 5(4):182-90.
    View in: PubMed
    Score: 0.070
  14. Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncol. 2014 Dec; 15(13):e594-e605.
    View in: PubMed
    Score: 0.069
  15. Circadian pharmacodynamics of anticancer therapies. Clin Chem. 1993 Nov; 39(11 Pt 2):2413-8.
    View in: PubMed
    Score: 0.064
  16. Circadian cancer therapy. J Clin Oncol. 1993 Jul; 11(7):1403-17.
    View in: PubMed
    Score: 0.063
  17. Circadian cancer pharmacodynamics. Ann Ist Super Sanita. 1993; 29(4):705-10.
    View in: PubMed
    Score: 0.061
  18. NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: particular relevance to triple negative subgroup. Breast Cancer Res Treat. 2012 Jul; 134(2):881-8.
    View in: PubMed
    Score: 0.058
  19. The multifrequency (circadian, fertility cycle, and season) balance between host and cancer. Ann N Y Acad Sci. 1991; 618:228-56.
    View in: PubMed
    Score: 0.053
  20. Cancer chronotherapy: a drug delivery challenge. Prog Clin Biol Res. 1990; 341A:1-10.
    View in: PubMed
    Score: 0.049
  21. Timing may be a critical factor in drug therapy. Cancer Treat Rep. 1987 Dec; 71(12):1321.
    View in: PubMed
    Score: 0.043
  22. Circadian clock coordinates cancer cell cycle progression, thymidylate synthase, and 5-fluorouracil therapeutic index. Mol Cancer Ther. 2006 Aug; 5(8):2023-33.
    View in: PubMed
    Score: 0.039
  23. Chemotherapy via implanted infusion pump: new perspectives for delivery of long-term continuous treatment. Oncol Nurs Forum. 1986 Mar-Apr; 13(2):17-24.
    View in: PubMed
    Score: 0.038
  24. Screening and breast cancer. N Engl J Med. 2006 Feb 16; 354(7):767-9; author reply 767-9.
    View in: PubMed
    Score: 0.038
  25. Circadian timing of cancer chemotherapy. Science. 1985 Apr 05; 228(4695):73-5.
    View in: PubMed
    Score: 0.035
  26. Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia. J Oncol Pract. 2017 06; 13(6):e562-e573.
    View in: PubMed
    Score: 0.021
  27. Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells. JAMA Oncol. 2016 Jan; 2(1):134-6.
    View in: PubMed
    Score: 0.019
  28. Erythropoietin usage in patients with cancer. Cancer J Sci Am. 1995 Nov-Dec; 1(4):243-6.
    View in: PubMed
    Score: 0.018
  29. The rationale for non-zero-order drug delivery using automatic, computer-based drug delivery systems (chronotherapy). J Biol Response Mod. 1987 Dec; 6(6):587-98.
    View in: PubMed
    Score: 0.011
  30. Randomized phase II trial of high-dose melatonin and radiation therapy for RPA class 2 patients with brain metastases (RTOG 0119). Int J Radiat Oncol Biol Phys. 2007 Jul 01; 68(3):852-7.
    View in: PubMed
    Score: 0.010
  31. Comment to Anderson WF, Jatoi I, Devesa SS: distinct breast cancer incidence and prognostic patterns in the NCI'S SEER program: suggesting a possible link between etiology and outcome. Breast Cancer Res Treat 90:127-137, 2005. Breast Cancer Res Treat. 2006 Jun; 97(3):341-3.
    View in: PubMed
    Score: 0.010
  32. Cancer chronomics III. Chronomics for cancer, aging, melatonin and experimental therapeutics researchers. J Exp Ther Oncol. 2006; 6(1):73-84.
    View in: PubMed
    Score: 0.009
  33. The clinical application of chronobiology to oncology. Am J Anat. 1983 Dec; 168(4):519-42.
    View in: PubMed
    Score: 0.008
  34. Chronic lymphocytic leukemia in association with a second lymphoproliferative disorder: response to chemotherapy in two cases. Med Pediatr Oncol. 1979; 7(2):111-6.
    View in: PubMed
    Score: 0.006
  35. Current status of the therapy of advanced renal carcinoma. J Surg Oncol. 1977; 9(3):277-88.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.